birtamimab
Term · Oncology and biomedicine · MLC-T-ONC-012025
A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, birtamimab specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.
| Identifier | MLC-T-ONC-012025 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-amyloid monoclonal antibody NEOD001 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012025",
"term": "birtamimab",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, birtamimab specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.",
"synonyms": [
"anti-amyloid monoclonal antibody NEOD001"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/birtamimab/"
}
Record 3,596 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.